Background: This study aimed to investigate the correlation of microRNA (miRNA) expression profile with renal impairment (RI) risk in multiple myeloma (MM) patients.
Methods: Plasma cell samples were isolated from bone marrows of 20 RI-MM patients and 20 non-RI-MM patients, and then proposed to microarray assay. Then 5 candidate miRNAs were selected and further validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in plasma cell samples from bone marrows of 60 RI-MM patients and 60 non-RI-MM patients.
Results: Principal component analysis and heatmap analysis revealed that miRNA expression profile could clearly distinguish RI-MM patients from non-RI-MM patients, further Valcano plots identified 28 upregulated and 13 downregulated miRNAs in RI-MM patients compared to non-RI-MM patients, and enrichment analysis observed that these dysregulated miRNAs were enriched in renal/inflammatory/apoptosis pathways and renal/inflammatory diseases. Subsequent RT-qPCR validation discovered that miR-103a-3p, miR-449c-5p and let-7a-5p were greatly increased, while miR-877-5p and miR-455-3p were dramatically decreased in RI-MM patients compared to non-RI-MM patients, and all of them could predict RI risk in MM patients by receiver operating characteristic (ROC) curve analysis. Most importantly, the combination of these five miRNAs presented with a great predictive value for RI risk in MM patients with an area under the curve (AUC) of 0.934, 95% CI: 0.895-0.974.
Conclusions: MiRNA expression profile is closely implicated in the RI development, and miR-103a-3p, miR-449c-5p, miR-877-5p, miR-455-3p and let-7a-5p may serve as novel biomarkers for RI risk in MM patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798990 | PMC |
| http://dx.doi.org/10.21037/tcr.2020.01.41 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study.
Medicine (Baltimore)
June 2024
Sanofi, Cambridge, MA, USA.
Evidence on real-world clinical and economic outcomes in patients with multiple myeloma (MM) and renal impairment (RI) is limited in the United States. This retrospective study aimed to generate an updated comprehensive assessment of the clinical and economic outcomes of MM patients with RI using the Medicare research identifiable files data with Part D linkage, which might assist in assessing the total clinical and socioeconomic burden of these high-risk and challenging-to-treat patients. Treatment patterns and clinical and economic outcomes in first line (1L) to fourth line (4L) therapy were described in Medicare beneficiaries (2012 to 2018) for MM patients with RI (RI MM cohort).
View Article and Find Full Text PDFPrescribe to Save Lives: An Intervention to Increase Naloxone Prescribing Among HIV Clinicians.
J Addict Med
November 2023
From the University of Massachusetts Chan Medical School-Baystate, Springfield, MA (PDF, DW, RH); Center for Research on Healthcare, Section of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA (RJ); The Center for Health and Justice Transformation, The Miriam Hospital, Providence, RI (MM, JDR); The COBRE on Opioids and Overdose at Rhode Island Hospital, Providence, RI (SR, MM, TCG, JDR); The Warren Alpert Medical School of Brown University, Providence, RI (SR, JDR); Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA (AYW); Opioid Policy Research Collaborative, The Heller School for Social Policy and Management, Brandeis University, Waltham, MA (TCG); and the University of Rhode Island College of Pharmacy, Kingston, RI (JB).
Objectives: Overdose is a major cause of preventable death among persons living with HIV. This study aimed to increase HIV clinicians' naloxone prescribing, which can reduce overdose mortality.
Methods: We enrolled 22 Ryan White-funded HIV practices and implemented onsite, peer-to-peer training, posttraining academic detailing, and pharmacy peer-to-peer contact around naloxone prescribing in a nonrandomized stepped wedge design.
Dynamic regulation of inter-organelle communication by ubiquitylation controls skeletal muscle development and disease onset.
Elife
July 2023
Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Ubiquitin-proteasome system (UPS) dysfunction is associated with the pathology of a wide range of human diseases, including myopathies and muscular atrophy. However, the mechanistic understanding of specific components of the regulation of protein turnover during development and disease progression in skeletal muscle is unclear. Mutations in , an E3 ubiquitin ligase cullin3 (CUL3) substrate-specific adapter protein, result in severe congenital nemaline myopathy, but the events that initiate the pathology and the mechanism through which it becomes pervasive remain poorly understood.
View Article and Find Full Text PDFPotential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients.
Transl Cancer Res
March 2020
Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Background: This study aimed to investigate the correlation of microRNA (miRNA) expression profile with renal impairment (RI) risk in multiple myeloma (MM) patients.
Methods: Plasma cell samples were isolated from bone marrows of 20 RI-MM patients and 20 non-RI-MM patients, and then proposed to microarray assay. Then 5 candidate miRNAs were selected and further validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in plasma cell samples from bone marrows of 60 RI-MM patients and 60 non-RI-MM patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!